8-K 1 d752902d8k.htm 8-K 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 21, 2019

 

 

AMGEN INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-37702   95-3540776

(State or Other Jurisdiction

of Incorporation)

  (Commission File Number)  

(IRS Employer

Identification No.)

One Amgen Center Drive

Thousand Oaks, California

  91320-1799
(Address of Principal Executive Offices)   (Zip Code)

(805) 447-1000

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common stock, $0.0001 par value    AMGN    The NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 


Item 5.07. Submission of Matters to a Vote of Security Holders.

The Company held its Annual Meeting on May 21, 2019. The final results of the voting for each matter submitted to a vote of stockholders at the meeting are as follows:

Item 1 - Election of Directors

Each of the following 12 nominees for director were elected to serve a one-year term expiring at the Company’s 2020 annual meeting of stockholders and until his or her successor is elected and qualified, or until his or her earlier retirement, resignation, disqualification, removal or death.

 

Name    Votes For    Votes Against    Abstain   

Broker

Non-Votes

Dr. Wanda M. Austin

   454,806,146    1,042,775    1,521,000    92,311,761

Mr. Robert A. Bradway

   434,709,584    17,679,520      4,980,817    92,311,761

Dr. Brian J. Druker

   454,638,535    1,159,026    1,572,361    92,311,761

Mr. Robert A. Eckert

   446,036,161    9,750,834    1,583,125    92,311,563

Mr. Greg C. Garland

   438,192,636    17,573,215      1,603,806    92,312,026

Mr. Fred Hassan

   451,550,347    4,210,825    1,608,599    92,311,911

Dr. Rebecca M. Henderson

   454,742,698    1,132,209    1,498,414    92,308,361

Mr. Charles M. Holley, Jr.

   454,377,748    1,366,712    1,625,937    92,311,286

Dr. Tyler Jacks

   454,459,354    1,327,530    1,583,188    92,311,611

Ms. Ellen J. Kullman

   451,114,136    4,752,212    1,516,591    92,298,743

Dr. Ronald D. Sugar

   449,665,290    6,090,028    1,614,059    92,312,307

Dr. R. Sanders Williams

   453,234,955    2,537,557    1,597,409    92,311,761

Item 2 - Advisory Vote to Approve Our Executive Compensation

The advisory vote to approve our executive compensation was approved.

 

For:

   425,056,230

Against:

   29,468,700

Abstain:

   2,844,992

Broker Non-Votes:

   92,311,760

Item 3 - Ratification of Selection of Independent Registered Public Accountants

Ernst & Young LLP was ratified as the Company’s independent registered public accountants for the fiscal year ending December 31, 2019. No Broker Non-Votes resulted from the vote on this proposal.

 

For:

   528,869,016

Against:

   18,874,776

Abstain:

   1,937,891

No other matters were submitted for stockholder action.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    AMGEN INC.
Date: May 21, 2019     By:   /s/ Jonathan P. Graham
    Name:     Jonathan P. Graham
    Title:  

Senior Vice President, General Counsel and

Secretary